Natco Pharma Limited has issued a clarification to BSE Limited regarding the recent increase in trading volumes of its shares, attributing the surge to market-driven factors. The pharmaceutical company's response, dated February 25, 2026, addresses BSE's inquiry under reference L/SURV/ONL/PV/SG/2025-2026/935.

Regulatory Compliance and Disclosure

The company emphasized its adherence to regulatory requirements in its communication to the stock exchange. Key aspects of the clarification include:

Volume Movement Explanation

Natco Pharma stated that the increased trading volume in its shares is purely market-driven and results from prevailing market conditions. The company clarified that it has not withheld any material or price-sensitive information that could influence the volume behavior of its shares.

Corporate Communication Details

The clarification letter was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, on February 25, 2026. The response confirms that all disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, have been made, covering information that bears on the company's operations and performance.

Regulatory Framework

The communication falls under the standard regulatory framework where stock exchanges monitor unusual price or volume movements and seek clarifications from listed companies. Natco Pharma's response demonstrates its commitment to transparency and regulatory compliance in addressing market inquiries.

NATCO Pharma Limited has secured a significant regulatory milestone with the approval from India's Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide injection in the domestic market. The company made this announcement on February 14, 2026, through a regulatory filing under SEBI's Listing Obligations and Disclosure Requirements.

Product Launch and Market Entry

The pharmaceutical company plans to launch the generic Semaglutide injection in the Indian market in March 2026. This timeline indicates a swift market entry strategy following the regulatory approval.

Therapeutic Application

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. This approval allows NATCO Pharma to enter the competitive diabetes treatment segment with a generic version of this important therapeutic agent.

Company Profile and Manufacturing Capabilities

NATCO Pharma Limited operates as a research and development-oriented, science-driven pharmaceutical company with a strong focus on oncology in targeted therapies for the domestic market. The company also concentrates on limited competition molecules in the US market.

Manufacturing and Regulatory Infrastructure

The company's manufacturing capabilities include:

• 9 manufacturing sites across India
• 2 dedicated R&D facilities
• Regulatory approvals from multiple international authorities including U.S. FDA, Brazil ANVISA, Health Canada, and WHO
• Market presence in over 50 global markets

Business Segments

NATCO Pharma's diversified portfolio encompasses multiple pharmaceutical segments:

• Generic and branded pharmaceuticals
• Specialty pharmaceuticals
• Active pharmaceutical ingredients
• Crop protection products

This CDSCO approval for Semaglutide represents another addition to NATCO Pharma's expanding pharmaceutical portfolio, particularly strengthening its position in the diabetes treatment market segment in India.